What is HDR brachytherapy?
High dose-rate brachytherapy is also known as HDR brachytherapy, or temporary brachytherapy. It's a type of internal radiotherapy.
It involves inserting thin tubes into the prostate gland. A source of radiation is then passed down the tubes into the prostate for a few minutes to destroy cancer cells. The source of radiation is then removed, so no radiation is left in your body. Because the radiation is put directly into the prostate, the healthy tissue nearby gets a smaller dose of radiation. This means healthy tissue is less likely to be damaged than with another type of radiotherapy called external beam radiotherapy.
You may have HDR brachytherapy on its own or, more often, you will have it together with external beam radiotherapy. If you have external beam radiotherapy with HDR brachytherapy, you will get high doses of radiation to the whole prostate as well as to the area just outside the prostate. You may also have hormone therapy before and/or after HDR brachytherapy to shrink the prostate and make the treatment more effective.
There is another type of brachytherapy called permanent seed brachytherapy or low dose-rate brachytherapy, which involves implanting tiny radioactive seeds into the prostate
Who can have HDR brachytherapy?
HDR brachytherapy on its own
A few hospitals offer HDR brachytherapy on its own to treat cancer that hasn’t spread outside the prostate (localised prostate cancer), and has a low or medium risk of spreading.
HDR brachytherapy with other treatments
You may be offered HDR brachytherapy together with external beam radiotherapy if you have localised prostate cancer (cancer that hasn’t spread outside the prostate) or if you have locally advanced prostate cancer (cancer that has spread to just outside the prostate).
External beam radiotherapy is usually used in combination with hormone therapy to treat both localised and locally advanced prostate cancer. This means you may have three treatments together. The external beam radiotherapy treats the prostate and the area just outside the prostate. HDR brachytherapy gives an extra dose of radiotherapy to the prostate. You might hear this called a brachytherapy ‘boost’.
Having both external beam radiotherapy and hormone therapy can help to make the treatment more effective. But it can also increase the risk of side effects.
HDR brachytherapy can also treat cancer that has come back after radiotherapy (recurrent prostate cancer). This is called salvage brachytherapy.
HDR brachytherapy isn’t usually used to treat cancer that has spread to other parts of the body (advanced prostate cancer).
If you have localised or locally advanced prostate cancer, your Cambridge Prognostic Group (CPG) will help your doctor decide what treatment options are suitable for you. However, some doctors may use the old system of low, medium and high risk instead. Read more about CPG.
Other things that might affect whether you can have HDR brachytherapy
HDR brachytherapy may not be suitable for you if you have severe problems urinating, because the treatment can make these problems worse. These can include symptoms of an enlarged prostate such as a weak urine flow or not emptying your bladder properly. Before you have treatment, your doctor or nurse will ask you about any urinary problems and you may have some tests.
If you have recently had an operation called a transurethral resection of the prostate (TURP), you may have to wait three to six months before HDR brachytherapy can be considered. TURP is used to relieve symptoms of an enlarged prostate. Some hospitals don’t offer HDR brachytherapy to men who have had a TURP as there may be a higher risk of urinary problems afterwards.
If you have HDR brachytherapy, you may have a general anaesthetic during treatment which means you will be asleep and won’t feel anything. So you may only be able to have HDR brachytherapy if you are fit and healthy enough to have an anaesthetic. Although you may be able to have a spinal anaesthetic (epidural) instead. This may depend on what your hospital offers.
What other treatments might be available?
You might be able to have other treatments, depending on whether your cancer is localised, locally advanced or advanced. Read more about other treatment options.
What are the advantages and disadvantages?
An advantage for one person might not be for someone else. If you are offered HDR brachytherapy, speak to your doctor or nurse before deciding whether to have it. They can help you think about which treatment to have. There’s a list of questions below which you might find helpful. Give yourself time to think about whether HDR brachytherapy is right for you.
- HDR brachytherapy delivers a high dose of radiation directly into the prostate. This means healthy tissue nearby only gets a small dose of radiation and is less likely to be damaged and cause side effects.
- You will be in hospital for just one or two days for treatment.
- Recovery is quick, which means you can usually return to your normal activities within a week.
- If your cancer comes back, you may be able to have further treatment with hormone therapy.
- HDR brachytherapy gives a 'boost' of radiation to the prostate when used together with external beam radiotherapy, without causing extra damage to the surrounding healthy tissue.
- It can cause side effects such as urinary, bowel and erection problems.
- You will need an anaesthetic, which can have side effects.
- At some hospitals, you may need more than one radiation treatment. You may need to stay in the same position between treatments, with the tubes still in your prostate. Some men find this uncomfortable.
- It may be some time before you will know whether the treatment has been successful.
If you are having external beam radiotherapy as well as HDR brachytherapy, think about the advantages and disadvantages of both treatments. You may have more side effects if you have HDR brachytherapy and external beam radiotherapy.
What does treatment involve?
If you decide to have HDR brachytherapy, you will be referred to a specialist who treats cancer with radiotherapy, called a clinical oncologist. The treatment itself may be planned and carried out by specialists including therapy radiographers, radiologists, urologists, physicists and sometimes a specialist nurse.
If you have a large prostate, you may have hormone therapy for at least three months before brachytherapy starts, to shrink your prostate. If you have a higher risk cancer, you may have hormone therapy before and after treatment. You may also have a short course (three to five weeks) of external beam radiotherapy. You may have this before or after your HDR brachytherapy.
If you have localised or locally advanced prostate cancer, you may have hormone therapy for six months before brachytherapy treatment, during treatment and for up to three years after treatment.
On the morning of your treatment, you will have an enema to help you empty your bowels. An enema is a liquid medication which is inserted directly into your back passage (rectum). It’s important that your bowel is empty so that clear images of your prostate can be taken. The nurse may then give you a tablet to stop you needing to open your bowels when the radiation is being delivered.
You will probably have a general anaesthetic so that you are asleep during the procedure. But you may have a spinal anaesthetic (epidural), so that you are awake but can’t feel anything. Talk to your doctor about which type of anaesthetic you will have – it may depend on what your hospital offers.
Once you have had the anaesthetic, an ultrasound probe will be inserted into your back passage. This scans your prostate to make sure the tubes have been inserted in the right place. Thin tubes are then passed through the perineum, which is the area between the testicles and the opening of the back passage (anus), into the prostate and the surrounding tissues. There are normally 10 to 20 tubes, and once they are in the right position, they are secured in place.
You will also have a catheter fitted, which is a thin tube passed through the penis into the bladder to drain urine.
You will then have a scan – either a computerised tomography (CT) scan, magnetic resonance imaging (MRI) scan or ultrasound scan. Each hospital does things slightly differently and you may need more than one scan. Your doctor will use the scan to plan the doses of radiation needed for your treatment. Read more about scans.
You may still be asleep during the scan, or you may be awake. If you are awake, you will need to lie still during the scan and your treatment. Some men find this uncomfortable.
During treatment, the tubes in your prostate are attached to the brachytherapy machine. A source of radiation attached to a wire is inserted into each tube in turn. The radiation source stays in each tube for a set period of time – usually a few minutes. The machine automatically removes the source of radiation at the end of the treatment.
Most hospitals just do one treatment, but you may have more than one. This will depend on your hospital. Check with your doctor or nurse how many treatments you will have, and whether you will be asleep or awake during treatment.
In some hospitals, you will have the treatment while you are asleep in the operating theatre and the tubes will be removed before you wake up. In other hospitals, you will have the treatment in the brachytherapy room while you’re awake. The treatment itself is completely painless. The tubes are removed after the treatment has finished.
Two or three treatments in total
If you have more than one treatment, there will be a gap of at least six hours between each one. You will have each treatment in the brachytherapy room while you are awake.
Some hospitals will leave the tubes in place in between each treatment. Some men find this uncomfortable. You normally have to lie on your back and keep still to make sure the tubes don’t move. Some men find it a long time to lie still.
Other hospitals will remove the tubes after each treatment, and insert new ones for the next treatment. Ask your doctor or nurse how they will carry out the treatments.
After the treatment has finished, the nurse will take your catheter out. This might be uncomfortable but should not be painful. Some hospitals will leave the catheter in overnight, until the blood starts to clear from your urine.
Many people feel fine after anaesthetic but some people have side effects such as feeling sick or dizzy. Some men find it difficult to urinate after treatment. You can go home when you have recovered from the anaesthetic and can urinate normally. This may be on the same day as treatment but some men need to stay in hospital overnight.
You shouldn’t drive for 24 to 48 hours after the anaesthetic. Ask a family member or friend to take you home.
Your doctor or nurse will give you any medicines that you need at home. These may include drugs to help prevent urinary problems (such as tamsulosin) and antibiotics to prevent infection. You may be given pain-relieving drugs such as paracetamol or ibuprofen.
You may notice some blood in your urine for a few days after your treatment. You may also have some discomfort and bruising in the area where the tubes were placed. Your bowel movements may also feel a little uncomfortable. This should settle down after a few days.
No radioactive material is left in the prostate, and you won’t give off any radiation. So it’s safe for you to be around other people, including children and pregnant women.
If you are having external beam radiotherapy after the HDR brachytherapy, you will start this around two weeks after your brachytherapy.
What should I look out for after treatment?
Your doctor or nurse will give you a telephone number to call if you have any questions or concerns. Contact them or go to your local accident and emergency (A&E) department if any of the following happen.
- If your urine is very bloody or has clots in it, this could mean you have bleeding in your prostate. This may need treatment as soon as possible.
- If you are suddenly not able to urinate, this could be acute urinary retention. This will need treatment as soon as possible.
- If you have a high temperature (more than 38ºC or 101ºF) with or without chills, this may be a sign of infection.
What happens afterwards?
Going back to normal activities
You should be able to return to your normal activities a few days after treatment. You can go back to work as soon as you feel able – this will depend on how much physical effort your work involves. Speak to your doctor or nurse about your own situation.
Your follow-up appointment
You will have an appointment with your doctor or nurse a few weeks after your treatment. They will monitor how well you are recovering from the treatment and ask about any side effects. Read more about what to expect at a follow-up appointment.
Your PSA level should gradually drop to its lowest level (nadir) after 18 months to two years. How quickly this happens, and how low your PSA level falls, varies between men. If you have hormone therapy as well as HDR brachytherapy, your PSA may fall more quickly. Some PSA will still show up in tests because healthy prostate cells may still produce small amounts of PSA.
A sign that your cancer may have come back is if your PSA level has risen by 2ng/ml or more above its lowest level, or if it has risen for three or four PSA tests in a row.
If your PSA level does start to rise, talk to your doctor or nurse about what treatment might be suitable for you. Read more about treatment options if your cancer comes back.
Looking after yourself after brachytherapy
At some hospitals, you may not have many follow-up appointments after your treatment and be encouraged to take greater control of your own health and wellbeing. You might hear this called supported self-management.
Instead of having regular appointments at the hospital, you may talk to your doctor or nurse over the telephone. You’ll still have regular PSA tests to check how your cancer has responded to treatment (see above). But your GP may give you the results over the phone or in a letter. Some men prefer this type of follow-up, as it means you can avoid going to appointments when you’re feeling well and don’t have any concerns.
Your doctor or nurse will give you information about the possible side effects of your treatment and any symptoms to look out for, as well as details of who to call if you notice any changes.
You, or your doctor or nurse, can arrange an appointment at any point if you have any questions or concerns.
What are the side effects?
Like all treatments, HDR brachytherapy can cause side effects. These will affect each man differently, and you may not get all the possible side effects. Before you start treatment, talk to your doctor, nurse or radiographer about the side effects. Knowing what to expect can help you deal with them.
You may have more side effects if you have HDR brachytherapy and external beam radiotherapy together – although this doesn’t always happen. External beam radiotherapy can cause side effects months or even years after treatment.
You might also get more side effects if you had problems before treatment. For example, if you already had urinary, erection or bowel problems, you may find these are worse after HDR brachytherapy.
Tiredness and fatigue
You may feel tired for the first few days after treatment as you recover from the anaesthetic. The effect of radiation on the body may make you feel tired for longer, especially if you are on hormone therapy as well. If you are getting up a lot during the night to urinate, this can also make you feel tired in the day.
Fatigue is extreme tiredness that can affect your everyday life. It can affect your energy levels, your motivation and your emotions. Fatigue can continue after the treatment has finished and may last several months.If you are also having external beam radiotherapy, this can also cause tiredness.
There are things you can do to help manage fatigue. Read more about fatigue and managing fatigue. Or contact our Specialist Nurses.
HDR brachytherapy can cause urinary problems, including:
- irritation of the urethra and bladder (radiation cystitis)
- needing to urinate more often (urinary frequency)
- needing to urinate urgently (urinary urgency)
- difficulty emptying the bladder properly (urine retention).
Read more about urinary problems after brachytherapy and what might help.
HDR brachytherapy and external beam radiotherapy can both affect the blood vessels and nerves that control erections. This may cause problems getting and keeping an erection (erectile dysfunction). This may gradually get worse over several years, especially if you have external beam radiotherapy as well.
You may be more likely to have problems getting an erection if you had any erection problems before treatment, or if you have hormone therapy or external beam radiotherapy alongside brachytherapy.
There are ways to manage erection problems. Read more about erection problems and what might help.
Other sexual problems
Some men notice a reduced sensation along the penis immediately after HDR brachytherapy. This may slowly improve but it can occasionally be permanent.
You may find that you ejaculate less semen. Or you may have a ‘dry orgasm’ where you have the sensation of an orgasm, but don’t produce any semen.
Brachytherapy may make you infertile, which means you won’t be able to have children naturally. But there is still a chance that you could make someone pregnant after brachytherapy. It’s possible that the radiation could change your sperm and this might affect any children you conceive, although the risk of this is very low. If this is relevant to you, use contraception to avoid having a child for a while after treatment.
If you are planning on having children you may be able to store your sperm before you start treatment so that you can use it later for fertility treatment. If this is relevant to you, ask your doctor or nurse whether sperm storage is available locally.
The risk of bowel problems is low in men who have HDR brachytherapy. But you are more likely to have problems if you are also having external beam radiotherapy.
Bowel problems can include:
- passing more wind
- loose and watery bowel movements (diarrhoea)
- inflammation, pain and bleeding in the back passage (proctitis).
Bleeding from the back passage is a rare side effect of HDR brachytherapy. It can also be a sign of other bowel conditions such as bowel cancer, so tell your nurse or GP about any bleeding. They may do some tests to find out what is causing it. They will also be able to tell you about treatments that can help.
Using a rectal spacer to protect your back passage
Your doctor may suggest using a rectal spacer to help protect the inside of your back passage from radiation damage. The spacer is placed between your prostate and your back passage. Rectal spacers aren’t commonly used, so they might not be available at your hospital. Ask your doctor, nurse or radiographer for more information about rectal spacers, their side effects and other ways to manage bowel problems .
If you are gay or bisexual
If you are gay, bisexual, or a man who has sex with men, some of the side effects of HDR brachytherapy may cause specific issues for you.
If you are the active partner during anal sex you normally need a strong erection. If you have problems with erections, there are treatments that may help keep your erection hard enough for anal sex. Read more about erection problems and what might help.
If you are the receptive partner during anal sex, then bowel problems may be a particular issue. If you do have bowel problems, wait until these have improved before trying anal play or sex. Ask your doctor or nurse for more information or speak to our Specialist Nurses.
Questions to ask your doctor or nurse
- Will I have external beam radiotherapy before or after temporary brachytherapy?
- Do I need hormone treatment before and/or after temporary brachytherapy?
- What are the chances of side effects such as urinary problems, erection problems and bowel problems with this treatment?
- How many treatments will I have?
- Will I be asleep or awake during treatment?
- How long will I need to stay in hospital for the treatment?
- How will we know if the treatment has worked?
- What should my PSA level be after treatment and how often will you measure it?
- If my PSA continues to rise, what other treatments are available?
Updated: January 2023 |To be reviewed: January 2025
- Peter Bownes, Deputy Head of Radiotherapy Physics, Leeds Teaching Hospitals NHS Trust
- Peter Hoskin, Consultant Clinical Oncologist, Mount Vernon Cancer Centre and Division of Cancer Sciences
- Oliver Hulson, Consultant Radiologist, Leeds Teaching Hospitals NHS Trust
- Philip Reynolds, Consultant therapeutic radiographer, Clatterbridge Cancer Centre
- Our Specialist Nurses
- Our volunteers.
- Allott EH, Masko EM, Freedland SJ. Obesity and Prostate Cancer: Weighing the Evidence. Eur Urol. 2013 May;63(5):800–9.
- Berkey FJ. Managing the adverse effects of radiation therapy. Am Fam Physician. 2010 Aug 15;82(4):381–8, 394.
- Blank TO. Gay Men and Prostate Cancer: Invisible Diversity. J Clin Oncol. 2004 Sep 27;23(12):2593–6.
- Bourke L, Smith D, Steed L, Hooper R, Carter A, Catto J, et al. Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016 Apr;69(4):693–703.
- Cao Y, Ma J. Body Mass Index, Prostate Cancer-Specific Mortality, and Biochemical Recurrence: a Systematic Review and Meta-analysis. Cancer Prev Res (Phila Pa). 2011 Jan 13;4(4):486–501.
- Chao MWT, Grimm P, Yaxley J, Jagavkar R, Ng M, Lawrentschuk N. Brachytherapy: state-of-the-art radiotherapy in prostate cancer. BJU Int. 2015 Oct;116:80–8.
- Cornell D. A Gay Urologist’s Changing Views on Prostate Cancer. J Gay Lesbian Psychother. 2005 Feb 15;9(1–2):29–41.
- Crook J. The role of brachytherapy in the definitive management of prostate cancer. Cancer/Radiothérapie. 2011 Jun;15(3):230–7.
- Davies NJ, Batehup L, Thomas R. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer. 2011 Nov 8;105:S52–73.
- De Bari B, Daidone A, Alongi F. Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature. Crit Rev Oncol Hematol. 2015 Jun;94(3):360–70.
- Dempsey PJ. Creation of a protective space between the rectum and prostate prior to prostate radiotherapy using a hydrogel spacer. Clin Radiol. 2022;6.
- Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. Ann Oncol. 2012 Jan 6;23(7):1665–71.
- Gardner JR, Livingston PM, Fraser SF. Effects of Exercise on Treatment-Related Adverse Effects for Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Systematic Review. J Clin Oncol. 2014 Feb 1;32(4):335–46.
- Gaztañaga M, Crook J. Interpreting a rising prostate-specific antigen after brachytherapy for prostate cancer: Rising PSA after brachytherapy. Int J Urol. 2013 Feb;20(2):142–7.
- Gerdtsson A, Poon JB, Thorek DL, Mucci LA, Evans MJ, Scardino P, et al. Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. Eur Urol. 2015 Dec;68(6):1076–82.
- Hauswald H, Kamrava MR, Fallon JM, Wang PC, Park SJ, Van T, et al. High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results. Int J Radiat Oncol. 2016 Mar;94(4):667–74.
- Hechtman LM. Clinical Naturopathic Medicine [Internet]. Harcourt Publishers Group (Australia); 2014 [cited 2015 Jul 21]. 1610 p. Available from: http://www.bookdepository.com/Clinical-Naturopathic-Medicine-Leah-Hechtman/9780729541923
- Henson CC, Burden S, Davidson SE, Lal S. Nutritional interventions for reducing gastrointestinal toxicity in adults undergoing radical pelvic radiotherapy. Cochrane Database Syst Rev [Internet]. 2013 [cited 2014 Nov 18];(11). Available from: http://doi.wiley.com/10.1002/14651858.CD009896.pub2
- Ho T, Gerber L, Aronson WJ, Terris MK, Presti JC, Kane CJ, et al. Obesity, Prostate-Specific Antigen Nadir, and Biochemical Recurrence After Radical Prostatectomy: Biology or Technique? Results from the SEARCH Database. Eur Urol. 2012 Nov;62(5):910–6.
- Hoskin PJ, Colombo A, Henry A, Niehoff P, Paulsen Hellebust T, Siebert FA, et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: An update. Radiother Oncol. 2013 Jun;107(3):325–32.
- Hu MB, Xu H, Bai PD, Jiang HW, Ding Q. Obesity has multifaceted impact on biochemical recurrence of prostate cancer: a dose-response meta-analysis of 36,927 patients. Med Oncol Northwood Lond Engl. 2014 Feb;31(2):829.
- Husson O, Mols F, Poll-Franse LV van de. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Ann Oncol. 2010 Sep 24;mdq413.
- Jawad MS, Dilworth JT, Gustafson GS, Ye H, Wallace M, Martinez A, et al. Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer. Int J Radiat Oncol. 2016 Mar;94(4):657–66.
- Keilani M, Hasenoehrl T, Baumann L, Ristl R, Schwarz M, Marhold M, et al. Effects of resistance exercise in prostate cancer patients: a meta-analysis. Support Care Cancer. 2017 Jun 10;
- Keogh JWL, MacLeod RD. Body Composition, Physical Fitness, Functional Performance, Quality of Life, and Fatigue Benefits of Exercise for Prostate Cancer Patients: A Systematic Review. J Pain Symptom Manage. 2012 Jan;43(1):96–110.
- Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, et al. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU Int. 2011;110(4):492–8.
- Kubo K, Wadasaki K, Kimura T, Murakami Y, Kajiwara M, Teishima J, et al. Clinical features of prostate-specific antigen bounce after 125I brachytherapy for prostate cancer. J Radiat Res (Tokyo). 2018 Sep 1;59(5):649–55.
- Larkin D, Lopez V, Aromataris E. Managing cancer-related fatigue in men with prostate cancer: A systematic review of non-pharmacological interventions. Int J Nurs Pract. 2014 Oct;20(5):549–60.
- Lin PH, Aronson W, Freedland SJ. Nutrition, dietary interventions and prostate cancer: the latest evidence. BMC Med. 2015 Jan 8;13:3.
- Lopez P, Taaffe DR, Newton RU, Buffart LM, Galvão DA. What is the minimal dose for resistance exercise effectiveness in prostate cancer patients? Systematic review and meta-analysis on patient-reported outcomes. Prostate Cancer Prostatic Dis [Internet]. 2020 Nov 20 [cited 2021 Feb 25]; Available from: http://www.nature.com/articles/s41391-020-00301-4
- Luo R, Chen Y, Ran K, Jiang Q. Effect of obesity on the prognosis and recurrence of prostate cancer after radical prostatectomy: a meta-analysis. Transl Androl Urol. 2020 Dec;9(6):2713722–2712722.
- Magnuson WJ, Mahal A, Yu JB. Emerging Technologies and Techniques in Radiation Therapy. Semin Radiat Oncol. 2017 Jan 1;27(1):34–42.
- MD SEG. The Ups and Downs of Gay Sex After Prostate Cancer Treatment. J Gay Lesbian Psychother. 2005 Feb 15;9(1–2):43–55.
- Mendez LC, Morton GC. High dose-rate brachytherapy in the treatment of prostate cancer. Transl Androl Urol. 2018 Jun;7(3):357–70.
- Menichetti J, Villa S, Magnani T, Avuzzi B, Bosetti D, Marenghi C, et al. Lifestyle interventions to improve the quality of life of men with prostate cancer: A systematic review of randomized controlled trials. Crit Rev Oncol Hematol. 2016 Dec;108:13–22.
- Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, et al. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol. 2018 Jun 1;4(6):e180039–e180039.
- Mohamad H, McNeill G, Haseen F, N’Dow J, Craig LCA, Heys SD. The Effect of Dietary and Exercise Interventions on Body Weight in Prostate Cancer Patients: A Systematic Review. Nutr Cancer. 2015 Jan 2;67(1):43–60.
- Morgan TM, Press RH, Cutrell PK, Zhang C, Chen Z, Rahnema S, et al. Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques. J Contemp Brachytherapy. 2018;10(6):495–502.
- Morton G, Chung H, McGuffin M, D’Alimonte L, Zhang L, Ravi A, et al. Acute Toxicity and Early Patient Reported Outcomes in a Randomized Phase II Trial of High Dose-Rate Brachytherapy as Monotherapy in Low and Intermediate Risk Prostate Cancer. J Med Imaging Radiat Sci. 2017;48(1):S14.
- Mottet N, Cornford P, Van den Bergh, Briers E, Santis MD, Gillessen S, et al. EAU Guidelines on Prostate Cancer. European Association of Urology; 2021.
- National Institute for Health and Care Excellence. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. Interventional procedures guidance 590. 2017.
- National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management NG131 [Internet]. 2021. Available from: https://www.nice.org.uk/guidance/ng131/resources/prostate-cancer-diagnosis-and-management-pdf-66141714312133
- National Institute for Health and Care Excellence. Technology overview | The Oncentra Prostate v4.x for ultrasound‑guided real‑time HDR brachytherapy in men with localised prostate cancer | Advice | NICE [Internet]. National Institute for Health and Care Excellence; 2014 [cited 2019 Jul 24]. Available from: https://www.nice.org.uk/advice/mib16/chapter/Technology-overview
- Patel S, Demanes DJ, Ragab O, Zhang M, Veruttipong D, Nguyen K, et al. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer. Brachytherapy. 2017 Mar;16(2):299–305.
- Payne HA, Pinkawa M, Peedell C, Bhattacharyya SK, Woodward E, Miller LE. SpaceOAR hydrogel spacer injection prior to stereotactic body radiation therapy for men with localized prostate cancer: A systematic review. Medicine (Baltimore). 2021 Dec 10;100(49):e28111.
- Pettersson A, Johansson B, Persson C, Berglund A, Turesson I. Effects of a dietary intervention on acute gastrointestinal side effects and other aspects of health-related quality of life: A randomized controlled trial in prostate cancer patients undergoing radiotherapy. Radiother Oncol. 2012 Jun;103(3):333–40.
- Ralph, Sean, Richardson, Clifford. How Long Should Men Abstain from Receiving Anal Sex Following Treatments for Prostate Cancer? In 2019. p. 1.
- Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019 Apr;10(2):63–89.
- Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical Activity after Diagnosis and Risk of Prostate Cancer Progression: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer Res. 2011 May 24;71(11):3889–95.
- Strouthos I, Tselis N, Chatzikonstantinou G, Butt S, Baltas D, Bon D, et al. High dose rate brachytherapy as monotherapy for localised prostate cancer. Radiother Oncol. 2018 Feb 1;126(2):270–7.
- Teleni L, Chan RJ, Chan A, Isenring EA, Vela I, Inder WJ, et al. Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials. Endocr Relat Cancer. 2016 Jan 2;23(2):101–12.
- Tillisch K. Complementary and alternative medicine for functional gastrointestinal disorders. Gut. 2006 May 1;55(5):593–6.
- Tran S, Boissier R, Perrin J, Karsenty G, Lechevallier E. Review of the Different Treatments and Management for Prostate Cancer and Fertility. Urology. 2015 Nov;86(5):936–41.
- Tselis N, Hoskin P, Baltas D, Strnad V, Zamboglou N, Rödel C, et al. High Dose Rate Brachytherapy as Monotherapy for Localised Prostate Cancer: Review of the Current Status. Clin Oncol R Coll Radiol G B. 2017 Jul;29(7):401–11.
- Wallace T, Anscher M. BMJ best practice: prostate cancer. [Internet]. 2018. Available from: https://bestpractice.bmj.com/topics/en-gb/254/pdf/254.pdf
- Wang LS, Murphy CT, Ruth K, Zaorsky NG, Smaldone MC, Sobczak ML, et al. Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer. Cancer. 2015 Sep 1;121(17):3010–7.
- Wedlake LJ, Shaw C, Whelan K, Andreyev HJN. Systematic review: the efficacy of nutritional interventions to counteract acute gastrointestinal toxicity during therapeutic pelvic radiotherapy. Aliment Pharmacol Ther. 2013 Jun;37(11):1046–56.
- Wolin KY, Luly J, Sutcliffe S, Andriole GL, Kibel AS. Risk of Urinary Incontinence Following Prostatectomy: The Role of Physical Activity and Obesity. J Urol. 2010 Feb;183(2):629–33.
- World Cancer Research Fund. Diet, nutrition, physical activity and prostate cancer. Anal Res Cancer Prev Surviv. 2014 Revised 2018;53.
- World Cancer Research Fund International. Continuous Update Project report: Diet, Nutrition, Physical Activity and Prostate Cancer [Internet]. 2014. Available from: www.wcrf.org/sites/default/files/Prostate-Cancer-2014-Report.pdf
- Zaorsky NG, Doyle LA, Yamoah K, Andrel JA, Trabulsi EJ, Hurwitz MD, et al. High dose rate brachytherapy boost for prostate cancer: A systematic review. Cancer Treat Rev. 2014 Apr;40(3):414–25.
- Zapatero A, Guerrero A, Maldonado X, Álvarez A, González-San Segundo C, Cabeza Rodriguez MA, et al. Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial. Int J Radiat Oncol. 2016 Oct 1;96(2):341–8.
- Zdravkovic A, Hasenöhrl T, Palma S, Crevenna R. Effects of resistance exercise in prostate cancer patients. 2020;(132):452–63.